The 2024 ESC AF guideline acknowledges the role of inflammation—listing C-reactive protein among factors associated with incident AF and noting that biomarkers such as interleukin-6 may reflect residual stroke risk—yet it does not recommend routine biomarker-based stratification; consequently, clinically actionable inflammatory biomarkers beyond high-sensitivity CRP remain limited (3). The gene discussed is IL6; the disease is atrial fibrillation.